Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD171-specific CAR T-cells for Recurrent/Refractory Neuroblastoma
NCT02311621Phase 1Active, not recruiting
- Sponsor
- Seattle Children's
- Start
- Nov 2014
- Primary completion
- Nov 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of L1CAM-specific CAR T-cells in neuroblastoma and ganglioneuroblastoma (GNB) (3 arms), sponsored by Seattle Children's. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Nov 2014; status: active, not recruiting.
02
Drugs
L1CAM-specific CAR T-cells
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)
Beyond the preview
Go deeper on NCT02311621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02311621.